Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jun 15;83(2):171–176. doi: 10.1054/bjoc.2000.1234

Limited neuropeptide Y precursor processing in unfavourable metastatic neuroblastoma tumours

P Bjellerup 1, E Theodorsson 3, H Jörnvall 4, P Kogner 2
PMCID: PMC2363490  PMID: 10901366

Abstract

Neuropeptide Y (NPY) is found at high concentrations in neural crest-derived tumours and has been implicated as a regulatory peptide in tumour growth and differentiation. Neuroblastomas, ganglioneuromas and phaeochromocytomas with significant concentrations of NPY-like immunoreactivity were investigated for different molecular forms of NPY and for significance of proNPY processing. Gel-permeation chromatography identified intact NPY (1–36) in all tumours, whereas proNPY (69 amino acids) was detected only in control adrenal tissue and malignant neuroblastomas. Purification of NPY-like immunoreactivity in tumour extracts and structural characterization revealed that both NPY (1–36) and the truncated form NPY (3–36) was present. The degree of processing of proNPY to NPY in tumour tissue was lower in advanced neuroblastomas with regional or metastatic spread (stage 3 and 4) (n = 6), (41%, 12–100%, median, range), compared to the less aggressive stage 1, 2 and 4S tumours (n = 12), (93%; 69–100%), (P = 0.012). ProNPY processing of less than 50% was correlated with poor clinical outcome (P = 0.004). MYCN oncogene amplification was also correlated to a low degree of proNPY processing (P = 0.025). In summary, a low degree of proNPY processing was correlated to clinical advanced stage and poor outcome in neuroblastomas. ProNPY/NPY processing generated molecular forms of NPY with known differences in NPY-receptor selectivity, implicating a potential for in vivo modulation of NPY-like effects in tumour tissue. © 2000 Cancer Research Campaign

Keywords: neuropeptide Y, neuroblastoma, phaeochromocytoma, NPY processing, NPY (3–36), proNPY, prohormone processing

Full Text

The Full Text of this article is available as a PDF (80.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adrian T. E., Allen J. M., Bloom S. R., Ghatei M. A., Rossor M. N., Roberts G. W., Crow T. J., Tatemoto K., Polak J. M. Neuropeptide Y distribution in human brain. Nature. 1983 Dec 8;306(5943):584–586. doi: 10.1038/306584a0. [DOI] [PubMed] [Google Scholar]
  2. Adrian T. E., Allen J. M., Terenghi G., Bacarese-Hamilton A. J., Brown M. J., Polak J. M., Bloom S. R. Neuropeptide Y in phaeochromocytomas and ganglioneuroblastomas. Lancet. 1983 Sep 3;2(8349):540–542. doi: 10.1016/s0140-6736(83)90570-6. [DOI] [PubMed] [Google Scholar]
  3. Allen J. M. Molecular structure of neuropeptide Y. Ann N Y Acad Sci. 1990;611:86–98. doi: 10.1111/j.1749-6632.1990.tb48924.x. [DOI] [PubMed] [Google Scholar]
  4. Allen J. M., Yeats J. C., Causon R., Brown M. J., Bloom S. R. Neuropeptide Y and its flanking peptide in human endocrine tumors and plasma. J Clin Endocrinol Metab. 1987 Jun;64(6):1199–1204. doi: 10.1210/jcem-64-6-1199. [DOI] [PubMed] [Google Scholar]
  5. Brodeur G. M., Azar C., Brother M., Hiemstra J., Kaufman B., Marshall H., Moley J., Nakagawara A., Saylors R., Scavarda N. Neuroblastoma. Effect of genetic factors on prognosis and treatment. Cancer. 1992 Sep 15;70(6 Suppl):1685–1694. doi: 10.1002/1097-0142(19920915)70:4+<1685::aid-cncr2820701607>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  6. Brodeur G. M., Pritchard J., Berthold F., Carlsen N. L., Castel V., Castelberry R. P., De Bernardi B., Evans A. E., Favrot M., Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466–1477. doi: 10.1200/JCO.1993.11.8.1466. [DOI] [PubMed] [Google Scholar]
  7. Corder R., Emson P. C., Lowry P. J. Purification and characterization of human neuropeptide Y from adrenal-medullary phaeochromocytoma tissue. Biochem J. 1984 May 1;219(3):699–706. doi: 10.1042/bj2190699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dötsch J., Christiansen H., Hänze J., Lampert F., Rascher W. Plasma neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue neuropeptide Y. Regul Pept. 1998 Sep 25;75-76:185–190. doi: 10.1016/s0167-0115(98)00067-6. [DOI] [PubMed] [Google Scholar]
  9. Grandt D., Schimiczek M., Rascher W., Feth F., Shively J., Lee T. D., Davis M. T., Reeve J. R., Jr, Michel M. C. Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors. Regul Pept. 1996 Nov 14;67(1):33–37. doi: 10.1016/s0167-0115(96)00104-8. [DOI] [PubMed] [Google Scholar]
  10. Hedborg F., Lindgren P. G., Johansson I., Kogner P., Samuelsson B. O., Bekassy A. N., Olsen L., Kreuger A., Påhlman S. N-myc gene amplification in neuroblastoma: a clinical approach using ultrasound guided cutting needle biopsies collected at diagnosis. Med Pediatr Oncol. 1992;20(4):292–300. doi: 10.1002/mpo.2950200405. [DOI] [PubMed] [Google Scholar]
  11. Hook V. Y., Schiller M. R., Azaryan A. V. The processing proteases prohormone thiol protease, PC1/3 and PC2, and 70-kDa aspartic proteinase show preferences among proenkephalin, proneuropeptide Y, and proopiomelanocortin substrates. Arch Biochem Biophys. 1996 Apr 1;328(1):107–114. doi: 10.1006/abbi.1996.0149. [DOI] [PubMed] [Google Scholar]
  12. Jekel P. A., Weijer W. J., Beintema J. J. Use of endoproteinase Lys-C from Lysobacter enzymogenes in protein sequence analysis. Anal Biochem. 1983 Oct 15;134(2):347–354. doi: 10.1016/0003-2697(83)90308-1. [DOI] [PubMed] [Google Scholar]
  13. Katzenstein H. M., Cohn S. L. Advances in the diagnosis and treatment of neuroblastoma. Curr Opin Oncol. 1998 Jan;10(1):43–51. doi: 10.1097/00001622-199801000-00008. [DOI] [PubMed] [Google Scholar]
  14. Kogner P., Björk O., Theodorsson E. Neuropeptide Y in neuroblastoma: increased concentration in metastasis, release during surgery, and characterization of plasma and tumor extracts. Med Pediatr Oncol. 1993;21(5):317–322. doi: 10.1002/mpo.2950210502. [DOI] [PubMed] [Google Scholar]
  15. Kogner P. Neuropeptides in neuroblastomas and ganglioneuromas. Prog Brain Res. 1995;104:325–338. doi: 10.1016/s0079-6123(08)61798-7. [DOI] [PubMed] [Google Scholar]
  16. Langley K. The neuroendocrine concept today. Ann N Y Acad Sci. 1994 Sep 15;733:1–17. doi: 10.1111/j.1749-6632.1994.tb17251.x. [DOI] [PubMed] [Google Scholar]
  17. Lee J. E., Evans D. B. Advances in the diagnosis and treatment of gastrointestinal neuroendocrine tumors. Cancer Treat Res. 1997;90:227–238. doi: 10.1007/978-1-4615-6165-1_12. [DOI] [PubMed] [Google Scholar]
  18. Lundberg J. M., Terenius L., Hökfelt T., Martling C. R., Tatemoto K., Mutt V., Polak J., Bloom S., Goldstein M. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand. 1982 Dec;116(4):477–480. doi: 10.1111/j.1748-1716.1982.tb07171.x. [DOI] [PubMed] [Google Scholar]
  19. Mentlein R., Dahms P., Grandt D., Krüger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept. 1993 Dec 10;49(2):133–144. doi: 10.1016/0167-0115(93)90435-b. [DOI] [PubMed] [Google Scholar]
  20. Mentlein R. Proline residues in the maturation and degradation of peptide hormones and neuropeptides. FEBS Lett. 1988 Jul 18;234(2):251–256. doi: 10.1016/0014-5793(88)80092-9. [DOI] [PubMed] [Google Scholar]
  21. Michel M. C., Beck-Sickinger A., Cox H., Doods H. N., Herzog H., Larhammar D., Quirion R., Schwartz T., Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev. 1998 Mar;50(1):143–150. [PubMed] [Google Scholar]
  22. O'Hare M. M., Schwartz T. W. Expression and precursor processing of neuropeptide Y in human and murine neuroblastoma and pheochromocytoma cell lines. Cancer Res. 1989 Dec 15;49(24 Pt 1):7015–7019. [PubMed] [Google Scholar]
  23. O'Hare M. M., Schwartz T. W. Expression and precursor processing of neuropeptide Y in human pheochromocytoma and neuroblastoma tumors. Cancer Res. 1989 Dec 15;49(24 Pt 1):7010–7014. [PubMed] [Google Scholar]
  24. Oberg K. Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol. 1998 Jan;10(1):58–65. [PubMed] [Google Scholar]
  25. Paquet L., Massie B., Mains R. E. Proneuropeptide Y processing in large dense-core vesicles: manipulation of prohormone convertase expression in sympathetic neurons using adenoviruses. J Neurosci. 1996 Feb 1;16(3):964–973. doi: 10.1523/JNEUROSCI.16-03-00964.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pollak M. N., Schally A. V. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med. 1998 Feb;217(2):143–152. doi: 10.3181/00379727-217-44216. [DOI] [PubMed] [Google Scholar]
  27. Rehfeld J. F., Bardram L., Hilsted L. Gastroenteropancreatic tumours and prohormones. Scand J Gastroenterol Suppl. 1996;216:39–45. doi: 10.3109/00365529609094559. [DOI] [PubMed] [Google Scholar]
  28. Seeger R. C., Brodeur G. M., Sather H., Dalton A., Siegel S. E., Wong K. Y., Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985 Oct 31;313(18):1111–1116. doi: 10.1056/NEJM198510313131802. [DOI] [PubMed] [Google Scholar]
  29. Shaw C., Cormican K., Thim L., Maule A. G., Sloan J. M., Buchanan K. D. Neuropeptide Y and neuropeptide Y 3-36: isolation from human pancreatic endocrine tumours. Regul Pept. 1993 Jun 11;45(3):387–394. doi: 10.1016/0167-0115(93)90365-f. [DOI] [PubMed] [Google Scholar]
  30. Shorter N. A., Pence J. C. Retinoic acid-induced regulation of neuropeptide Y receptor expression and function in the neuroepithelioma line SK-N-MC. J Pediatr Surg. 1997 May;32(5):721–723. doi: 10.1016/s0022-3468(97)90014-2. [DOI] [PubMed] [Google Scholar]
  31. Theodorsson-Norheim E., Hemsén A., Lundberg J. M. Radioimmunoassay for neuropeptide Y (NPY): chromatographic characterization of immunoreactivity in plasma and tissue extracts. Scand J Clin Lab Invest. 1985 Jun;45(4):355–365. doi: 10.3109/00365518509161019. [DOI] [PubMed] [Google Scholar]
  32. Wulff B. S., Johansen T. E., Dalbøge H., O'Hare M. M., Schwartz T. W. Processing of two homologous precursors, pro-neuropeptide Y and pro-pancreatic polypeptide, in transfected cell lines expressing different precursor convertases. J Biol Chem. 1993 Jun 25;268(18):13327–13335. [PubMed] [Google Scholar]
  33. Zukowska-Grojec Z., Karwatowska-Prokopczuk E., Rose W., Rone J., Movafagh S., Ji H., Yeh Y., Chen W. T., Kleinman H. K., Grouzmann E. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res. 1998 Jul 27;83(2):187–195. doi: 10.1161/01.res.83.2.187. [DOI] [PubMed] [Google Scholar]
  34. Zukowska-Grojec Z., Pruszczyk P., Colton C., Yao J., Shen G. H., Myers A. K., Wahlestedt C. Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells. Peptides. 1993 Mar-Apr;14(2):263–268. doi: 10.1016/0196-9781(93)90040-n. [DOI] [PubMed] [Google Scholar]
  35. deS Senanayake P., Denker J., Bravo E. L., Graham R. M. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest. 1995 Nov;96(5):2503–2509. doi: 10.1172/JCI118310. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES